Terns Pharmaceuticals Stock Beta
| TERN Stock | USD 5.44 0.15 2.84% |
Terns Pharmaceuticals fundamentals help investors to digest information that contributes to Terns Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Terns Stock. The fundamental analysis module provides a way to measure Terns Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Terns Pharmaceuticals stock.
Terns | Beta |
Terns Pharmaceuticals Company Beta Analysis
Terns Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Terns Pharmaceuticals Beta | -0.65 |
Most of Terns Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Terns Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Terns Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Terns Pharmaceuticals is extremely important. It helps to project a fair market value of Terns Stock properly, considering its historical fundamentals such as Beta. Since Terns Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Terns Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Terns Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Terns Pharmaceuticals has a Beta of -0.646. This is 175.12% lower than that of the Pharmaceuticals sector and 146.47% lower than that of the Health Care industry. The beta for all United States stocks is notably higher than that of the company.
Terns Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Terns Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Terns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics of similar companies.Terns Pharmaceuticals is currently under evaluation in beta category among related companies.
Terns Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Terns Pharmaceuticals from analyzing Terns Pharmaceuticals' financial statements. These drivers represent accounts that assess Terns Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Terns Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 461.5M | 462.1M | 178.7M | 366.8M | 462.5M | 434.9M | |
| Enterprise Value | 449.2M | 400.1M | 131.0M | 224.8M | 383.1M | 356.9M |
Terns Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Terns Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Terns Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Terns Pharmaceuticals' value.| Shares | Hhg Plc | 2023-12-31 | 1.4 M | Great Point Partners Llc | 2023-12-31 | 1.3 M | Driehaus Capital Management Llc | 2023-12-31 | 1.1 M | Perceptive Advisors Llc | 2023-12-31 | 1.1 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.1 M | State Street Corporation | 2023-12-31 | 886.9 K | Geode Capital Management, Llc | 2023-12-31 | 840.5 K | Decheng Capital Llc | 2023-12-31 | 714.3 K | Longwood Capital Partners Llc | 2023-12-31 | 555.3 K | Orbimed Advisors, Llc | 2023-12-31 | 7.6 M | Vivo Capital, Llc | 2023-12-31 | 6.7 M |
As returns on the market increase, returns on owning Terns Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Terns Pharmaceuticals is likely to outperform the market.
Terns Fundamentals
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 88.87 M | ||||
| Shares Outstanding | 64.67 M | ||||
| Shares Owned By Insiders | 1.86 % | ||||
| Shares Owned By Institutions | 98.14 % | ||||
| Number Of Shares Shorted | 4.4 M | ||||
| Price To Book | 1.30 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (101.68 M) | ||||
| Net Income | (90.21 M) | ||||
| Cash And Equivalents | 139.81 M | ||||
| Cash Per Share | 5.51 X | ||||
| Total Debt | 603 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 3.95 X | ||||
| Cash Flow From Operations | (67.73 M) | ||||
| Short Ratio | 4.57 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 14.21 | ||||
| Number Of Employees | 66 | ||||
| Beta | -0.65 | ||||
| Market Capitalization | 351.83 M | ||||
| Total Asset | 268.52 M | ||||
| Retained Earnings | (332.63 M) | ||||
| Working Capital | 255.49 M | ||||
| Net Asset | 268.52 M |
About Terns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Terns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Terns Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Terns Pharmaceuticals' short interest history, or implied volatility extrapolated from Terns Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:Check out Terns Pharmaceuticals Piotroski F Score and Terns Pharmaceuticals Altman Z Score analysis. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Terns Stock analysis
When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.035 | Return On Assets (0.23) | Return On Equity (0.34) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.